Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration

Sponsor
Medical University of Vienna
Study ID
NCT01027468
Status
Completed

Conditions

  • Neovascular Age-related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

200 eyes with each subtype of neovascular age-related macular degeneration will be included in this study and 3 years after the initial intravitreal bevacizumab, best-corrected visual acuity (BCVA) will be measured using Snellen charts at 6m. Central retinal thickness (CRT) will be measured using Stratus OCT and Cirrus SD-OCT (Zeiss). Data of treatment-naive eyes (group 1) were compared to the data of eyes that had undergone prior treatment with photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide (group 2).

Key Dates

First listed
Dec 8, 2009
Start date
Aug 31, 2009
Status verified
Apr 2019
Primary completion
Nov 30, 2009
Completion
Dec 31, 2009

Study Design

Enrollment
160 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: group 1
    bevacizumab intravitreal injection

Primary Outcome Measure

Vision [ Time Frame: 3 years after first intravitreal bevacizumab treatment ]

Related Studies